- PR Newswire•11 days ago
LEUVEN, Belgium, March 16, 2017 /PRNewswire/ -- - Innovative Diabetic Eye Disease C linical and P re- C linical Portfolio - Provides "Multiple S hots on G oal " - First Patients Enrolled in ...
- PR Newswire•3 months ago
ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company, focused on developing novel medicines for diabetic eye disease, announces the enrollment of the first patients in a Phase II, single-masked, multicenter exploratory study evaluating the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular edema (DME). THR-317 (anti-PIGF) is a recombinant human monoclonal antibody directed against the receptor-binding site of human placental growth factor (PlGF). The trial will also assess THR-317's ability to improve best-corrected visual acuity (BCVA) and to reduce central retinal thickness in subjects with DME.
- PR Newswire•8 months ago
ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)
LEUVEN, Belgium, August 8, 2016 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye diseases, today announces that the results ...
THR.BR : Summary for THROMBOGENICS - Yahoo Finance
ThromboGenics NV (THR.BR)
Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
|Bid||2.96 x 10000|
|Ask||3.01 x 500000|
|Day's Range||3.00 - 3.08|
|52 Week Range||2.50 - 3.88|
|PE Ratio (TTM)||-2.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|